**Title:** Indian CRDMOs Thrive Amid Global Supply Chain Shifts
**Meta Description:** Investors are optimistic about Indian CRDMOs as the global pharmaceutical supply chain shifts away from China, signaling growth potential in the sector.
**URL Slug:** indian-crdmos-global-supply-chain-shift
**Headline:** Indian CRDMOs Poised for Growth as Global Pharmaceutical Supply Chains Shift from China
The global pharmaceutical supply chain is undergoing a significant transformation, with a notable shift away from China. This change has sparked considerable interest among investors in Indian contract research, development, and manufacturing organizations (CRDMOs). These companies provide a range of services, from early-stage drug discovery to late-stage drug development, positioning themselves as key players in the evolving market.
Export-focused CRDMOs such as Anthem Biosciences, Sai Life Sciences, and Divi’s Laboratories are currently trading at high valuations, reflecting investor enthusiasm as pharmaceutical innovators seek to diversify and mitigate risks in their operations. However, experts caution that while these CRDMOs are expected to experience substantial growth, their financial results have yet to fully demonstrate this potential.
Anthem Biosciences, based in Bengaluru, made a remarkable entrance on the stock exchanges on July 21, listing on the National Stock Exchange at a 27% premium over its initial public offering (IPO) price of ₹570. The IPO, which had an issue size of ₹3,395.79 crore, was oversubscribed by 67.42 times. As of July 25, Anthem’s stock was trading at a price-to-earnings (PE) ratio of 93.24. Ajay Bhardwaj, the managing director and CEO, expressed optimism, stating, “The good news is that… China is a behemoth. So, we have that much headroom to grow.”
According to the commerce ministry, approximately 65% of India’s imported bulk drugs and advanced drug intermediates, valued at $3.5 billion for FY25, originated from China. In response, the Indian government aims to bolster local manufacturing through an enhanced production-linked incentive scheme, promoting self-sufficiency in bulk drugs essential for medicine production.
Currently, the Indian CRDMO industry is valued at $3-3.5 billion, representing only 2-3% of the global CRDMO market, which is estimated at $145 billion. A recent report by BCG and IPSO indicates that the industry has grown at a compound annual growth rate of 15% from 2019 to 2024. The sector is at a pivotal moment, characterized by strong fundamentals and significant growth potential, driven by competitive advantages in small molecule capabilities, quicker startup times, and a focus on quality and cost efficiency.
Sai Life Sciences, which debuted in December 2024, was trading at ₹837 on July 25, nearing its peak of approximately ₹851, valuing the company at around 102 times its trailing earnings and about 8.2 times its book value. Other companies like Divi’s Laboratories and Syngene International also traded at premium valuations, with PE ratios of 80.31 and 55.09, respectively. In contrast, major generic pharmaceutical companies have more modest valuations, with Sun Pharmaceutical Industries at a PE ratio of 37.37, Dr. Reddy’s Laboratories at 18.84, and Cipla at 23.53.
Since its listing on the NSE, Sai Life Sciences shares have risen over 18%. Divi’s Laboratories saw a 35.56% increase from July 30, 2024, to July 28, 2025, while Piramal Pharma and Syngene International also experienced notable gains.
In conclusion, as the global pharmaceutical landscape shifts, Indian CRDMOs are well-positioned to capitalize on emerging opportunities, although their financial performance will be closely watched in the coming years.
**FAQ:**
**What are CRDMOs and why are they important?**
CRDMOs, or contract research, development, and manufacturing organizations, provide essential services in the pharmaceutical industry, facilitating drug discovery and development processes. Their role is increasingly vital as companies seek to diversify supply chains and enhance operational resilience.
